DOCSLIB.ORG

LAST 12 MONTH PREVALENCE of TOP 20 DRUGS Top 20 Drugs – Last 12 Months – Whole Sample (N=78,819)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
LAST 12 MONTH PREVALENCE of TOP 20 DRUGS Top 20 Drugs – Last 12 Months – Whole Sample (N=78,819) LAST 12 MONTH PREVALENCE OF TOP 20 DRUGS Top 20 Drugs – Last 12 Months – Whole Sample (N=78,819) Poppers 3.8 Ritalin 3.9 Electronic THC 3.9 Mystery White Powders 4.7 Ketamine 5.7 Caffeine Tablets 6.2 Nitrous Oxide 6.3 Benzodiazepines 7.8 Opioid Painkillers 8.7 LSD 10.1 Magic Mushrooms 10.6 Amphetamines* 11.7 Electonic CigareJes 12.3 Cocaine 16.4 Shisha Tobacco 18.5 MDMA* 23.4 Caffeinated Energy Drinks 45.9 Cannabis* 48.2 Tobacco 56.7 Alcohol 90.8 0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0 % last year prevalence *Denotes all types and preparaons Global Drug Survey GDS2014© Not to be reproduced without authors permission Top 20 Drugs – Last 12 Months – Australia (N=5,943) Synthe2c Cannabis 4.1 Ketamine 4.1 Mystery White Powders 4.5 Nitrous Oxide 4.8 Caffeine Tablets 4.9 Viagra 5.1 Poppers 5.8 Shisha Tobacco 6.5 Electronic CigareJes 6.7 Magic Mushrooms 7.9 LSD 9.4 Amphetamines* 11.8 Benzodiazepines 16.2 Opioid Painkillers 17.9 Cocaine 20.6 MDMA* 23.0 Caffeinated Energy Drinks 33.2 Cannabis* 34.7 Tobacco 36.4 Alcohol 92.1 0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0 % last year prevalence *Denotes all types and preparaons Global Drug Survey GDS2014© Not to be reproduced without authors permission Top 20 Drugs – Last 12 Months – Belgium (N=2,717) Poppers 4.1 2CB 4.6 Mystery White Powders 4.7 Benzodiazepines 5.2 Nutmeg 5.2 Ritalin 5.5 LSD 5.9 Ketamine 6.5 Nitrous Oxide 6.9 Electronic CigareJes 7.6 Opioid Painkillers 8.3 Amphetamines* 8.5 Magic Mushrooms 8.7 Shisha Tobacco 12.5 Cocaine 19.9 MDMA* 23.6 Cannabis* 41.8 Caffeinated Energy Drinks 49.0 Tobacco 59.3 Alcohol 95.3 0.0 20.0 40.0 60.0 80.0 100.0 120.0 % last year prevalence *Denotes all types and preparaons Global Drug Survey GDS2014© Not to be reproduced without authors permission Top 20 Drugs – Last 12 Months – Brazil (N=1,088) Amphetamines* 2.6 DMT 3.2 Opioid Painkillers 3.2 Mystery White Powders 3.7 Salvia Divinorum 3.8 Ritalin 3.9 Caffeine Tablets 4.4 Shisha Tobacco 4.5 Viagra 4.8 Ayahuasca 4.9 Electronic CigareJes 5.2 Magic Mushrooms 7.5 Benzodiazepines 9.7 MDMA* 13.8 Cocaine* 19.2 LSD 33.0 Caffeinated Energy Drinks 51.1 Tobacco 51.8 Cannabis* 69.5 Alcohol 89.7 0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0 % last year prevalence *Denotes all types and preparaons Global Drug Survey GDS2014© Not to be reproduced without authors permission Top 20 Drugs – Last 12 Months – Denmark (N=1,647) Tramadol 3.6 DMT 3.6 Mystery White Powders 3.7 2CB 5.7 Caffeine Tablets 6.0 Benzodiazepines 6.5 Ketamine 7.3 Opioid Painkillers 8.1 Nitrous Oxide 8.3 Ritalin 8.7 LSD 11.9 Amphetamines* 16.7 Electronic CigareJes 18.2 Magic Mushrooms 21.2 MDMA* 22.5 Cocaine 24.2 Caffeinated Energy Drinks 49.0 Tobacco 65.4 Cannabis* 66.0 Alcohol 92.5 0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0 % last year prevalence *Denotes all types and preparaons Global Drug Survey GDS2014© Not to be reproduced without authors permission Top 20 Drugs – Last 12 Months – France (N=2,051) Opium 2.6 Mystery White Powders 3.1 Z Drugs 3.3 Tramadol 3.4 Salvia Divinorum 3.5 Ketamine 5.3 Benzodiazepines 7.2 Amphetamines* 8.3 Poppers 9.0 Opioid Painkillers 9.3 LSD 9.4 Magic Mushrooms 12.5 Shisha Tobacco 13.0 Electronic CigareJes 22.8 MDMA* 23.1 Cocaine 24.4 Caffeinated Energy Drinks 37.9 Cannabis* 66.6 Tobacco 74.2 Alcohol 94.3 0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0 % last year prevalence *Denotes all types and preparaons Global Drug Survey GDS2014© Not to be reproduced without authors permission Top 20 Drugs – Last 12 Months – Germany (N=22,801) Benzodiazepines 3.4 Nitrous Oxide 3.5 Mystery White Powders 3.5 Ritalin 4.0 Nutmeg 4.1 Ketamine 4.7 Intranasal Caffeine 5.4 Electronic THC 5.7 LSD 7.8 Magic Mushrooms 9.2 Caffeine Tablets 9.4 Electronic CigareJes 9.9 Cocaine 12.7 Amphetamines* 17.1 MDMA* 21.5 Shisha Tobacco 29.1 Cannabis* 45.8 Caffeinated Energy Drinks 51.0 Tobacco 65.6 Alcohol 95.5 0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0 % last year prevalence *Denotes all types and preparaons Global Drug Survey GDS2014© Not to be reproduced without authors permission Top 20 Drugs – Last 12 Months – Hungary (N=3,239) Tramadol 1.0 Salvia Divinorum 1.1 DMT 1.1 2CB 1.1 Mephedrone 1.2 Kratom 1.5 Ketamine 1.7 Viagra 1.8 Nutmeg 2.0 Nitrous Oxide 2.7 Poppers 2.8 Caffeine Tablets 3.9 Synthe2c Cannabis 4.1 Mystery White Powders 5.0 LSD 5.3 Benzodiazepines 6.0 Electronic CigareJes 8.5 Magic Mushrooms 9.7 Cocaine 10.1 Amphetamines* 12.8 MDMA* 12.8 Shisha Tobacco 21.5 Cannabis* 37.6 Caffeinated Energy Drinks 49.9 Tobacco 61.5 Alcohol 94.1 0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0 % last year prevalence *Denotes all types and preparaons Global Drug Survey GDS2014© Not to be reproduced without authors permission Top 20 Drugs – Last 12 Months – Mexico (N=643) Poppers 3.6 Viagra 3.6 Ayahuasca 4.0 Mescaline 4.4 DMT 4.5 Mystery White Powders 4.8 Peyote 6.4 Amphetamines* 8.1 Benzodiazepines 9.5 Electronic CigareJes 9.8 Magic Mushrooms 10.0 Salvia Divinorum 10.3 Shisha Tobacco 19.0 Cocaine 25.7 MDMA* 26.9 LSD 32.5 Caffeinated Energy Drinks 42.8 Tobacco 66.9 Cannabis* 77.5 Alcohol 94.1 0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0 % last year prevalence *Denotes all types and preparaons Global Drug Survey GDS2014© Not to be reproduced without authors permission Top 20 Drugs – Last 12 Months – Netherlands (N=2,807) Benzodiazepines 3.8 Mystery White Powders 4.7 Opioid Painkillers 4.9 Poppers 6.2 LSD 7.0 GHB / GBL 7.2 Ritalin 9.3 2CB 9.5 Ketamine 12.0 Magic Mushrooms 14.0 Electronic CigareJes 14.5 Amphetamines* 22.0 Shisha Tobacco 22.4 Cocaine 23.7 Nitrous Oxide 26.5 Cannabis* 46.0 MDMA* 50.6 Caffeinated Energy Drinks 61.8 Tobacco 66.0 Alcohol 96.7 0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0 % last year prevalence *Denotes all types and preparaons Global Drug Survey GDS2014© Not to be reproduced without authors permission Top 20 Drugs – Last 12 Months – New Zealand (N=5,731) Cocaine 3.2 Nitrous Oxide 3.2 Magic Mushrooms 4.6 Amphetamines* 4.9 Caffeine Tablets 5.0 Ritalin 5.1 Mystery White Powders 5.3 Z Drugs 5.5 Electronic CigareJes 6.2 Benzodiazepines 6.8 Synthe2c Cannabis 6.8 Shisha Tobacco 7.1 LSD 7.9 Tramadol 11.5 MDMA* 13.1 Opioid Painkillers 19.1 Tobacco 33.5 Cannabis* 35.3 Caffeinated Energy Drinks 46.2 Alcohol 91.0 0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0 % last year prevalence *Denotes all types and preparaons Global Drug Survey GDS2014© Not to be reproduced without authors permission Top 20 Drugs – Last 12 Months – Portugal (N=630) Nitrous Oxide 1.4 Crack Cocaine 1.4 2CB 1.6 Opioid Painkillers 1.6 Nutmeg 1.8 Synthe2c Cannabis 2.1 Salvia Divinorum 2.5 Mystery White Powders 2.7 Electronic CigareJes 3.2 Magic Mushrooms 4.1 Amphetamines* 4.3 LSD 8.1 Benzodiazepines 8.7 Cocaine 10.3 MDMA* 13.3 Shisha Tobacco 15.9 Caffeinated Energy Drinks 37.0 Cannabis* 51.3 Tobacco 63.8 Alcohol 92.2 0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0 % last year prevalence *Denotes all types and preparaons Global Drug Survey GDS2014© Not to be reproduced without authors permission Top 20 Drugs – Last 12 Months – Republic of Ireland (N=838) 2CI 4.3 Caffeine Tablets 4.8 Nitrous Oxide 5.1 Tramadol 5.9 Amphetamines* 8.2 Mystery White Powders 9.2 2CB 10.4 Ketamine 10.4 LSD 11.6 Magic Mushrooms 12.9 Benzodiazepines 13.1 Shisha Tobacco 14.4 Opioid Painkillers 14.7 Electronic CigareJes 19.0 Cocaine 24.3 MDMA* 45.2 Caffeinated Energy Drinks 50.1 Cannabis* 59.4 Tobacco 66.7 Alcohol 95.1 0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0 % last year prevalence *Denotes all types and preparaons Global Drug Survey GDS2014© Not to be reproduced without authors permission Top 20 Drugs – Last 12 Months – Scotland (N=631) Tramadol 7.0 Caffeine Tablets 8.1 2CB 9.0 Amphetamines* 9.2 Mystery White Powders 9.3 Nitrous Oxide 10.0 Poppers 10.8 Shisha Tobacco 10.9 Magic Mushrooms 11.3 LSD 12.7 Benzodiazepines 12.7 Ketamine 14.7 Opioid Painkillers 15.5 Electronic CigareJes 20.3 Cocaine 26.3 MDMA* 39.6 Caffeinated Energy Drinks 46.3 Cannabis* 55.8 Tobacco 57.2 Alcohol 94.3 0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0 % last year prevalence *Denotes all types and preparaons Global Drug Survey GDS2014© Not to be reproduced without authors permission Top 20 Drugs – Last 12 Months – Spain (N=1,318) Ritalin 2.6 Electronic THC 2.7 Opium 2.7 2CB 3.0 Poppers 3.1 Opioid Painkillers 4.2 Ketamine 5.5 Mystery White Powders 6.4 LSD 8.7 Benzodiazepines 10.2 Electronic CigareJes 11.2 Magic Mushrooms 13.3 Shisha Tobacco 14.2 Amphetamines* 16.9 Cocaine 29.4 MDMA* 32.9 Caffeinated Energy Drinks 42.2 Tobacco 66.5 Cannabis* 66.8 Alcohol 93.6 0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0 % last year prevalence *Denotes all types and preparaons Global Drug Survey GDS2014© Not to be reproduced without authors permission Top 20 Drugs – Last 12 Months – Switzerland (N=5,133) Opioid Painkillers 2.7 Nutmeg 3.3 Intranasal Caffeine 3.4 Benzodiazepines 3.4 Nitrous Oxide 3.6 Poppers 3.6 Ritalin 4.0 Electronic THC 4.5 Caffeine Tablets 4.6 Magic Mushrooms 5.7 LSD 6.5 Amphetamines* 9.1 Cocaine 12.1 Eletronic CigareJes 12.9 MDMA* 15.5 Shisha Tobacco 26.1 Cannabis* 41.0 Caffeinated Energy Drinks 52.3 Tobacco 63.8 Alcohol 93.1 0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0 % last year prevalence *Denotes all types and preparaons Global Drug Survey GDS2014© Not to be reproduced without authors permission Top 20 Drugs – Last 12 Months – United Kingdom (N=7,326) 2CB 7.7 Mephedrone 7.9 Caffeine Tablets 8.3 Amphetamines* 9.7 Poppers 9.7 Mystery White Powders 10.9 LSD 12.2 Benzodiazepines 12.4 Magic Mushrooms 13.7
Load more

Recommended publications
  • Anaesthesia and Past Use Of
    177 Correspondence were using LSD. It is more popular than other commonly Anaesthesia and past use of used hallucinogens whose quoted incidence of clients are: LSD ketamine 0.1% (super-K/vitamin K.I), psilocybin and psilocin 0.6% (the active alkaloids in the Mexican "magic To the Editor: mushroom"), and 3,4 methylenedioxymethamphetamine We report the case of a 43-yr-old lady who was admitted ~MDMA" 1% (ecstasy). The effects of the concurrent to the Day Surgery Unit for release of her carpal tunnel ingestion of LSD on anaesthesia are well described. 2-4 retinaculum. During the preoperative visit, she reported The long-term effects of the past use of LSD are largely no intercurrent illnesses, drug therapy or allergies. She unknown. We wonder if the hallucinations experienced did say, however, that she was frightened of general anaes- by our patient during anaesthesia were due to her LSD thesia, since she had experienced terrifying dreams during intake many years before. We would be interested to surgery under general anaesthesia on three occasions dur- know if others have had experience anaesthetising patients ing the previous ten years. On further questioning, she who are past users of phencyclidine-derived drugs. admitted that she had used lysergic acid diethylamide (LSD) during the late 1960's, the last occasion being 1968 Geoffrey N. Morris MRCGPFRCA when she had experienced characterstic hallucinations. Patrick T. Magee MSe FRCA She had not experienced hallucinations in the ensuing Anaesthetic Department years, except on the surgical occasions mentioned. Royal United Hospital One of the three previous operations had been per- Combe Park formed at our hospital and the anaesthetic record was Bath BA1 3NG checked.
    [Show full text]
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
    [Show full text]
  • Evidence for the Involvement of Spinal Cord 1 Adrenoceptors in Nitrous
    Anesthesiology 2002; 97:1458–65 © 2002 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Evidence for the Involvement of Spinal Cord ␣ 1 Adrenoceptors in Nitrous Oxide–induced Antinociceptive Effects in Fischer Rats Ryo Orii, M.D., D.M.Sc.,* Yoko Ohashi, M.D.,* Tianzhi Guo, M.D.,† Laura E. Nelson, B.A.,‡ Toshikazu Hashimoto, M.D.,* Mervyn Maze, M.B., Ch.B.,§ Masahiko Fujinaga, M.D.ʈ Background: In a previous study, the authors found that ni- opioid peptide release in the brain stem, leading to the trous oxide (N O) exposure induces c-Fos (an immunohisto- 2 activation of the descending noradrenergic inhibitory chemical marker of neuronal activation) in spinal cord ␥-ami- nobutyric acid–mediated (GABAergic) neurons in Fischer rats. neurons, which results in modulation of the pain–noci- 1 In this study, the authors sought evidence for the involvement ceptive processing in the spinal cord. Available evi- Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/97/6/1458/337059/0000542-200212000-00018.pdf by guest on 01 October 2021 ␣ of 1 adrenoceptors in the antinociceptive effect of N2O and in dence suggests that at the level of the spinal cord, there activation of GABAergic neurons in the spinal cord. appear to be at least two neuronal systems that are Methods: Adult male Fischer rats were injected intraperitone- involved (fig. 1). In one of the pathways, activation of ally with ␣ adrenoceptor antagonist, ␣ adrenoceptor antago- 1 2 ␣ nist, opioid receptor antagonist, or serotonin receptor antago- the 2 adrenoceptors produces either direct presynaptic nist and, 15 min later, were exposed to either air (control) or inhibition of neurotransmitter release from primary af- 75% N2O.
    [Show full text]
  • Tramadol (Ultram)
    TRAMADOL (ULTRAM) Tramadol is FDA approved for the treatment of musculoskeletal pain. Studies have shown it is useful in treating the pain associated with diabetic neuropathy and other pain conditions. Tramadol comes in 50 mg tablets. The maximum dose is two tablets four times per day unless your kidney function is below normal or you are over 75 years old, in which case the maximum dose is two tablets three times per day. The main side effects of Tramadol are drowsiness, sedation, and stomach upset, all of which are minimized by slowly raising the dose. About 5% of patients have stomach upset at any dose of Tramadol and cannot take the medicine. Other risks include seizures (occur in less than 1/100,000 and are more likely if you have seizures) and possibly abuse (relevant if you have abused drugs in the past). Tramadol should be started at a low dose and raise the dose slowly toward the maximum dose. Start with one tablet at bedtime. After 3 - 7 days, increase to one tablet twice daily (morning and bedtime). After an additional 3 - 7 days, increase to one tablet three times per day (morning, noon, and bedtime). After an additional 3 - 7 days, increase to one tablet four times per day (1 tablet with each meal and 1 at bedtime). At that point, the dose may be increased or adjusted depending on how you are doing. To increase further, you will: Add a second tablet at bedtime (one tablet three times per day and two tablets at bedtime). After 3 - 7 days, add a second tablet to another dose (one tablet twice per day and two tablets twice per day).
    [Show full text]
  • Effects of Prophylactic Ketamine and Pethidine to Control Postanesthetic Shivering: a Comparative Study
    Biomedical Research and Therapy, 5(12):2898-2903 Original Research Effects of prophylactic ketamine and pethidine to control postanesthetic shivering: A comparative study Masoum Khoshfetrat1, Ali Rosom Jalali2, Gholamreza Komeili3, Aliakbar Keykha4;∗ ABSTRACT Background: Shivering is an undesirable complication following general anesthesia and spinal anesthesia, whose early control can reduce postoperative metabolic and respiratory complications. Therefore, this study aims to compare the effects of prophylactic injection of ketamine and pethi- dine on postoperative shivering.Methods: This double-blind clinical trial was performed on 105 patients with short-term orthopedic and ENT surgery. The patients were randomly divided into three groups; 20 minutes before the end of the surgery, 0.4 mg/kg of pethidine was injected to the first group, 0.5 mg/kg of ketamine was injected to the second group, and normal saline was injected to the third group. After the surgery, the tympanic membrane temperature was measured at 0, 10, 20, and 30 minutes. The shivering was also measured by a four-point grading from zero (no shiv- ering) to four (severe shivering). Data were analyzed by one-way ANOVA, Kruskal Wallis, Chi-square 1Doctor of Medicine (MD), Fellow of and Pearson correlation. Results: The mean age of patients was 35.811.45 years in the ketamine Critical Care Medicine (FCCM), group, 34.811.64 years in the normal saline group, and 33.1110.5 years in the pethidine group. Department of Anesthesiology and The one-way ANOVA showed no significant difference in the mean age between the three groups Critical Care, Khatam-Al-Anbiya (P=0.645).
    [Show full text]
  • 5-HT2A and 5-HT2C/2B Receptor Subtypes Modulate
    5-HT2A and 5-HT2C/2B Receptor Subtypes Modulate Dopamine Release Induced in Vivo by Amphetamine and Morphine in Both the Rat Nucleus Accumbens and Striatum Grégory Porras, M.S., Vincenzo Di Matteo, Ph.D., Claudia Fracasso, B.S., Guillaume Lucas, Ph.D., Philippe De Deurwaerdère, Ph.D., Silvio Caccia, Ph.D., Ennio Esposito, M.D., Ph.D., and Umberto Spampinato, M.D., Ph.D. In vivo microdialysis and single-cell extracellular neuron firing rate in both the ventral tegmental area and recordings were used to assess the involvement of the substantia nigra pars compacta was unaffected by SR serotonin2A (5-HT2A) and serotonin2C/2B (5-HT2C/2B) 46349B (0.1 mg/kg i.v.) but significantly potentiated by SB receptors in the effects induced by amphetamine and 206553 (0.1 mg/kg i.v.). These results show that 5-HT2A morphine on dopaminergic (DA) activity within the and 5-HT2C receptors regulate specifically the activation of mesoaccumbal and nigrostriatal pathways. The increase in midbrain DA neurons induced by amphetamine and DA release induced by amphetamine (2 mg/kg i.p.) in the morphine, respectively. This differential contribution may nucleus accumbens and striatum was significantly reduced be related to the specific mechanism of action of the drug by the selective 5-HT2A antagonist SR 46349B (0.5 mg/kg considered and to the neuronal circuitry involved in their s.c.), but not affected by the 5-HT2C/2B antagonist SB effect on DA neurons. Furthermore, these results suggest 206553 (5 mg/kg i.p.). In contrast, the enhancement of that 5-HT2C receptors selectively modulate the impulse accumbal and striatal DA output induced by morphine (2.5 flow–dependent release of DA.
    [Show full text]
  • Current Awareness in Clinical Toxicology Editors: Damian Ballam Msc and Allister Vale MD
    Current Awareness in Clinical Toxicology Editors: Damian Ballam MSc and Allister Vale MD February 2016 CONTENTS General Toxicology 9 Metals 38 Management 21 Pesticides 41 Drugs 23 Chemical Warfare 42 Chemical Incidents & 32 Plants 43 Pollution Chemicals 33 Animals 43 CURRENT AWARENESS PAPERS OF THE MONTH How toxic is ibogaine? Litjens RPW, Brunt TM. Clin Toxicol 2016; online early: doi: 10.3109/15563650.2016.1138226: Context Ibogaine is a psychoactive indole alkaloid found in the African rainforest shrub Tabernanthe Iboga. It is unlicensed but used in the treatment of drug and alcohol addiction. However, reports of ibogaine's toxicity are cause for concern. Objectives To review ibogaine's pharmacokinetics and pharmacodynamics, mechanisms of action and reported toxicity. Methods A search of the literature available on PubMed was done, using the keywords "ibogaine" and "noribogaine". The search criteria were "mechanism of action", "pharmacokinetics", "pharmacodynamics", "neurotransmitters", "toxicology", "toxicity", "cardiac", "neurotoxic", "human data", "animal data", "addiction", "anti-addictive", "withdrawal", "death" and "fatalities". The searches identified 382 unique references, of which 156 involved human data. Further research revealed 14 detailed toxicological case reports. Current Awareness in Clinical Toxicology is produced monthly for the American Academy of Clinical Toxicology by the Birmingham Unit of the UK National Poisons Information Service, with contributions from the Cardiff, Edinburgh, and Newcastle Units. The NPIS is commissioned by Public Health England Current Awareness in Clinical Toxicology Editors: Damian Ballam MSc and Allister Vale MD February 2016 Current Awareness in Clinical Toxicology is produced monthly for the American Academy of Clinical Toxicology by the Birmingham Unit of the UK National Poisons Information Service, with contributions from the Cardiff, Edinburgh, and Newcastle Units.
    [Show full text]
  • HIV and Substance Use October 2016
    HIV and Substance Use October 2016 Fast Facts • Alcohol and other drugs can affect a person’s judgment and increase risk of getting or transmitting HIV. • In people living with HIV, substance use can worsen the overall consequences of HIV. • Social and structural factors make it difficult to prevent HIV among people who use substances. Substance use disorders, which are problematic patterns of using alcohol or another substance, such as crack cocaine, methamphetamine (“meth”), amyl nitrite (“poppers”), prescription opioids, and heroin, are closely associated with HIV and other sexually transmitted diseases. Injection drug use (IDU) can be a direct route of HIV transmission if people share needles, syringes, or other injection materials that are contaminated with HIV. However, drinking alcohol and ingesting, smoking, or inhaling drugs are also associated with increased risk for HIV. These substances alter judgment, which can lead to risky sexual behaviors (e.g., having sex without a condom, having multiple partners) that can make people more likely to get and transmit HIV. In people living with HIV, substance use can hasten disease progression, affect adherence to antiretroviral therapy (HIV medicine), and worsen the overall consequences of HIV. Commonly Used Substances and HIV Risk • Alcohol. Excessive alcohol consumption, notably binge drinking, can be an important risk factor for HIV because it is linked to risky sexual behaviors and, among people living with HIV, can hurt treatment outcomes. • Opioids. Opioids, a class of drugs that reduce pain, include both prescription drugs and heroin. They are associated with HIV risk behaviors such as needle sharing when injected and risky sex, and have been linked to a recent HIV outbreak.
    [Show full text]
  • Quantitative Drug Test Menu Section 2
    1 Guthrie Square, Sayre, PA 18840 Bill To: Client GMG Toxicology Laboratory Requisition Toll Free Phone (844) 617-4719 Insurance Request Date: _____/______/______ Medical Director: Hani Hojjati, MD Fax (570) 887-4729 Patient PATIENT INFORMATION (PLEASE PRINT IN BLACK INK) INSURANCE BILLING INFORMATION (PLEASE PRINT IN BLACK INK) Pt Last Name First M I PRIMARY Medicare Medicaid Other Ins. Self Spouse Child __ Subscriber Last Name First M Address Birth Date Sex M F Beneficiary/Member # Group # City Pt. SS# or MRN Claims Name and Address City ST ZIP ST ZIP Home Phone (Attach a copy of the patient's insurance card and information) SECONDARY Medicare Medicaid Other Ins. Self Spouse Child Employer Work Phone Subscriber Last Name First M Work Address City ST ZIP Beneficiary/Member # Group # __ CLIENT INFORMATION - REFERRING PHYSICIAN Claims Name and Address City ST ZIP Client Address: (Atttach a copy of the patient's insurance card and information) COLLECTION / REPORTING INFORMATION Copy to: FAX Results to __ CALL Results to Phone: Fax: Date Collected: Time Collected: AM PM Specimen Type: Urine Saliva Other ___________________ Physician Signature (legible - No Stamp) For Lab Use Only (Required for Medicare & Medicaid patient orders) Signed ABN Obtained Place Lab Label Here Contact Laboratory Medical Director (570-887-4719) with questions concerning medical necessity PHYSICIAN When ordering tests, the physician is required to make an independent medical necessity decision with regard to each test thelaboratory will bill. The physician also understands he or she is required NOTICE to (1) submit ICD-10 diagnosis supported in the patient's medical record as documentation of the medical necessity or (2) explain and have the patient sign an ABN.
    [Show full text]
  • Neurological Complications of Nitrous Oxide Abuse
    Katherine Shoults, MD Case report: Neurological complications of nitrous oxide abuse A patient who presented with limb paresthesia and B12 deficiency was eventually diagnosed with subacute combined degeneration neuropathy secondary to nitrous oxide abuse. Case data ABSTRACT: A 34-year-old female ary to nitrous oxide (“laughing gas”) A 34-year-old female presented with with a history of alcohol and crystal abuse that had affected B12 activa- a 2-week history of progressive bilat- methamphetamine abuse presented tion. The patient was continued on eral limb paresthesia and tenderness, to the emergency department with B12 therapy, neurology follow-up as well as an inability to balance. She limb paresthesia and difficulty walk- was arranged, and addiction coun- had been well previously, although ing. At a primary care visit a week seling services were recommended. she did have a history of alcohol and earlier her progressive neurological Unfortunately, the patient was lost crystal methamphetamine abuse. She compromise had been viewed in the to follow-up after discharge from the had abstained from crystal metham- context of anemia and she was start- hospital. Physicians should be aware phetamine for 5 years and from alco- ed on daily B12 injections. Further that nitrous oxide is easy to acquire hol for 2 months. She was working as a investigations in hospital revealed in the form of commercially available care aid and denied using illegal drugs diminished proprioception, hyperal- cartridges or whipped cream canis- currently, but reported she had been gesia with pinprick and temperature ters called “whippits” and abuse of inhaling nitrous oxide (“laughing tests, a wide-based high-steppage nitrous oxide is increasingly com- gas”) for 6 months, with an escalation gait, elevated levels of B12 and ho- mon.
    [Show full text]
  • From Sacred Plants to Psychotherapy
    From Sacred Plants to Psychotherapy: The History and Re-Emergence of Psychedelics in Medicine By Dr. Ben Sessa ‘The rejection of any source of evidence is always treason to that ultimate rationalism which urges forward science and philosophy alike’ - Alfred North Whitehead Introduction: What exactly is it that fascinates people about the psychedelic drugs? And how can we best define them? 1. Most psychiatrists will define psychedelics as those drugs that cause an acute confusional state. They bring about profound alterations in consciousness and may induce perceptual distortions as part of an organic psychosis. 2. Another definition for these substances may come from the cross-cultural dimension. In this context psychedelic drugs may be recognised as ceremonial religious tools, used by some non-Western cultures in order to communicate with the spiritual world. 3. For many lay people the psychedelic drugs are little more than illegal and dangerous drugs of abuse – addictive compounds, not to be distinguished from cocaine and heroin, which are only understood to be destructive - the cause of an individual, if not society’s, destruction. 4. But two final definitions for psychedelic drugs – and those that I would like the reader to have considered by the end of this article – is that the class of drugs defined as psychedelic, can be: a) Useful and safe medical treatments. Tools that as adjuncts to psychotherapy can be used to alleviate the symptoms and course of many mental illnesses, and 1 b) Vital research tools with which to better our understanding of the brain and the nature of consciousness. Classifying psychedelic drugs: 1,2 The drugs that are often described as the ‘classical’ psychedelics include LSD-25 (Lysergic Diethylamide), Mescaline (3,4,5- trimethoxyphenylathylamine), Psilocybin (4-hydroxy-N,N-dimethyltryptamine) and DMT (dimethyltryptamine).
    [Show full text]
  • Pharmacology – Inhalant Anesthetics
    Pharmacology- Inhalant Anesthetics Lyon Lee DVM PhD DACVA Introduction • Maintenance of general anesthesia is primarily carried out using inhalation anesthetics, although intravenous anesthetics may be used for short procedures. • Inhalation anesthetics provide quicker changes of anesthetic depth than injectable anesthetics, and reversal of central nervous depression is more readily achieved, explaining for its popularity in prolonged anesthesia (less risk of overdosing, less accumulation and quicker recovery) (see table 1) Table 1. Comparison of inhalant and injectable anesthetics Inhalant Technique Injectable Technique Expensive Equipment Cheap (needles, syringes) Patent Airway and high O2 Not necessarily Better control of anesthetic depth Once given, suffer the consequences Ease of elimination (ventilation) Only through metabolism & Excretion Pollution No • Commonly administered inhalant anesthetics include volatile liquids such as isoflurane, halothane, sevoflurane and desflurane, and inorganic gas, nitrous oxide (N2O). Except N2O, these volatile anesthetics are chemically ‘halogenated hydrocarbons’ and all are closely related. • Physical characteristics of volatile anesthetics govern their clinical effects and practicality associated with their use. Table 2. Physical characteristics of some volatile anesthetic agents. (MAC is for man) Name partition coefficient. boiling point MAC % blood /gas oil/gas (deg=C) Nitrous oxide 0.47 1.4 -89 105 Cyclopropane 0.55 11.5 -34 9.2 Halothane 2.4 220 50.2 0.75 Methoxyflurane 11.0 950 104.7 0.2 Enflurane 1.9 98 56.5 1.68 Isoflurane 1.4 97 48.5 1.15 Sevoflurane 0.6 53 58.5 2.5 Desflurane 0.42 18.7 25 5.72 Diethyl ether 12 65 34.6 1.92 Chloroform 8 400 61.2 0.77 Trichloroethylene 9 714 86.7 0.23 • The volatile anesthetics are administered as vapors after their evaporization in devices known as vaporizers.
    [Show full text]